(2-哌啶-3-基苯基)甲醇 | 879545-49-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: (2-哌啶-3-基苯基)甲醇
• 英文名称: [2-(Piperidin-3-yl)phenyl]methanol
• 英文别名: (2-piperidin-3-ylphenyl)methanol
• CAS: 879545-49-0
• 化学式: C₁₂H₁₇NO
• 分子量: 191.273
• InChiKey: WOYZOOQUMXHPKA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (2-哌啶-3-基苯基)甲醇 在 铬酸 作用下， 以 丙酮 为溶剂， 生成 2-(piperidin-3-yl)benzoic acid
  参考文献：
  名称：

  Designing Active Template Molecules by Combining Computational De Novo Design and Human Chemist's Expertise

  摘要：

  We used a new software tool for de novo design, the "Molecule Evoluator", to generate a number of small molecules. Explicit constraints were a relatively low molecular weight and otherwise limited functionality, for example, low numbers of hydrogen bond donors and acceptors, one or two aromatic rings, and a small number of rotatable bonds. In this way, we obtained a collection of scaffold- or templatelike molecules rather than fully "decorated" ones. We asked medicinal chemists to evaluate the suggested molecules for ease of synthesis and overall appeal, allowing them to make structural changes to the molecules for these reasons. On the basis of their recommendations, we synthesized eight molecules with an unprecedented (not patented) yet simple structure, which were subsequently tested in a screen of 83 drug targets, mostly G protein-coupled receptors. Four compounds showed affinity for biogenic amine targets (receptor, ion channel, and transport protein), reflecting the training of the medicinal chemists involved. Apparently the generation of leadlike solutions helped the medicinal chemists to select good starting points for future lead optimization, away from existing compound libraries.

  DOI：

  10.1021/jm061356+
• 作为产物：
  描述：

  二乙基(3-吡啶基)-硼烷 在 platinum(IV) oxide 、 四(三苯基膦)钯 盐酸 、 四丁基溴化铵 、 氢气 、 sodium carbonate 作用下， 以 乙醇 、 水 为溶剂， 150.0 ℃ 、303.98 kPa 条件下， 反应 72.2h， 生成 (2-哌啶-3-基苯基)甲醇
  参考文献：
  名称：

  Designing Active Template Molecules by Combining Computational De Novo Design and Human Chemist's Expertise

  摘要：

  We used a new software tool for de novo design, the "Molecule Evoluator", to generate a number of small molecules. Explicit constraints were a relatively low molecular weight and otherwise limited functionality, for example, low numbers of hydrogen bond donors and acceptors, one or two aromatic rings, and a small number of rotatable bonds. In this way, we obtained a collection of scaffold- or templatelike molecules rather than fully "decorated" ones. We asked medicinal chemists to evaluate the suggested molecules for ease of synthesis and overall appeal, allowing them to make structural changes to the molecules for these reasons. On the basis of their recommendations, we synthesized eight molecules with an unprecedented (not patented) yet simple structure, which were subsequently tested in a screen of 83 drug targets, mostly G protein-coupled receptors. Four compounds showed affinity for biogenic amine targets (receptor, ion channel, and transport protein), reflecting the training of the medicinal chemists involved. Apparently the generation of leadlike solutions helped the medicinal chemists to select good starting points for future lead optimization, away from existing compound libraries.

  DOI：

  10.1021/jm061356+

文献信息

• Designing Active Template Molecules by Combining Computational De Novo Design and Human Chemist's Expertise
  作者：Eric-Wubbo Lameijer、Reynier A. Tromp、Ronald F. Spanjersberg、Johannes Brussee、Adriaan P. IJzerman

  DOI：10.1021/jm061356+

  日期：2007.4.1

  We used a new software tool for de novo design, the "Molecule Evoluator", to generate a number of small molecules. Explicit constraints were a relatively low molecular weight and otherwise limited functionality, for example, low numbers of hydrogen bond donors and acceptors, one or two aromatic rings, and a small number of rotatable bonds. In this way, we obtained a collection of scaffold- or templatelike molecules rather than fully "decorated" ones. We asked medicinal chemists to evaluate the suggested molecules for ease of synthesis and overall appeal, allowing them to make structural changes to the molecules for these reasons. On the basis of their recommendations, we synthesized eight molecules with an unprecedented (not patented) yet simple structure, which were subsequently tested in a screen of 83 drug targets, mostly G protein-coupled receptors. Four compounds showed affinity for biogenic amine targets (receptor, ion channel, and transport protein), reflecting the training of the medicinal chemists involved. Apparently the generation of leadlike solutions helped the medicinal chemists to select good starting points for future lead optimization, away from existing compound libraries.